These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23321661)

  • 1. Treatment of urinary retention caused by uterine leiomyoma with a gonadotropin-releasing hormone agonist: case report and review.
    Chu CM; Dabney L; Hardart A
    Female Pelvic Med Reconstr Surg; 2013; 19(1):52-5. PubMed ID: 23321661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Cramer SF
    Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute urinary retention caused by a uterine leiomyoma: a case report.
    Novi JM; Shaunik A; Mulvihill BH; Morgan MA
    J Reprod Med; 2004 Feb; 49(2):131-2. PubMed ID: 15018444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration.
    Seyhan A; Ata B; Sidal B; Urman B
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):526-8. PubMed ID: 18239009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nulligravida with Large Uterine Leiomyoma: A Case Report.
    Maharjan S; Thapa M; Pokhrel M
    JNMA J Nepal Med Assoc; 2022 Jun; 60(250):577-580. PubMed ID: 35690986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary retention and voiding dysfunction in women with uterine leiomyoma: a case series.
    Yazdany T; Bhatia NN; Nguyen JN
    J Reprod Med; 2012; 57(9-10):384-9. PubMed ID: 23091984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
    McCluggage WG; Bharucha H
    Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
    Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
    Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
    Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
    Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Three cases of urinary retention caused by uterine leiomyoma].
    Kuroda K; Gotoh M; Okamura K; Ono Y; Ohshima S; Watanabe H; Odani K
    Hinyokika Kiyo; 1999 Feb; 45(2):115-7. PubMed ID: 10212785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T
    Yang S; Kong F; Hou R; Rong F; Ma N; Li S; Yang J
    Br J Radiol; 2017 May; 90(1073):20160760. PubMed ID: 28256923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
    Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
    Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
    Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
    Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist use before hysterectomy.
    Stovall TG; Summit RL; Washburn SA; Ling FW
    Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine fibroid embolization for patients with acute urinary retention.
    Haskal ZJ; Armijo-Medina H
    J Vasc Interv Radiol; 2008 Oct; 19(10):1503-5. PubMed ID: 18662887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.